Overview
Medical technologies firm's Q4 net sales rose 11.4%, beating analyst expectations
Adjusted EPS for Q4 increased 11.5%, beating analyst expectations
Company expects 2026 organic net sales growth of 8.0% to 9.5%
Outlook
Company expects 2026 organic net sales growth between 8.0% and 9.5%
Stryker forecasts 2026 adjusted EPS between $14.90 and $15.10
Company anticipates slightly positive impact from foreign exchange on 2026 results
Result Drivers
MEDSURG AND NEUROTECHNOLOGY GROWTH - Segment net sales increased 17.5% in Q4, driven by strong unit volume growth
ORTHOPAEDICS SEGMENT - Organic net sales increased 8.4% in Q4, driven by unit volume growth
OPERATING MARGIN IMPROVEMENT - Adjusted operating income margin increased 100 bps to 30.2% in Q4
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 net sales | Beat | $7.20 bln | $7.12 bln (25 Analysts) |
Q4 Adjusted EPS | Beat | $4.47 | $4.40 (25 Analysts) |
Q4 EPS | $2.20 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Stryker Corp is $432.50, about 20.9% above its January 28 closing price of $357.83
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago
Press Release: ID:nGNE9clt5n
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)